BEAM

MKT CAP:$3B

Beam Therapeutics Inc.

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$30.90+$3.76 (+13.87%)

Apr 23, 2026

Company Details

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta th...

CEO

John Evans

IPO Date

Feb 6, 2020

Website

www.beamtx.com

Key Metrics TTM

Revenue

$140M

+120.0% YoY

Net Income

-$80M

EPS (Diluted)

-$1.01

Free Cash Flow

-$360M

Revenue / Share

$1.33

Gross Margin

-126.1%

Operating Margin

-274.6%

Net Margin

-57.2%

FCF Margin

-257.7%

P/S

20.3x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Feb 24, 2026

$140M+120.0%EPS -$0.81

Q4 2025

Feb 24, 2026

$114M+279.5%EPS $2.33

Q3 2025

Nov 4, 2025

$10M-32.0%EPS -$1.10

Q2 2025

Aug 5, 2025

$8M-28.1%EPS -$1.00

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$8M	-$57M	-$76M
Q2 22	$17M	-$58M	-$82M
Q3 22	$16M	-$69M	-$91M
Q4 22	$20M	-$66M	-$89M
Q1 23	$24M	-$75M	-$99M
Q2 23	$20M	-$77M	-$102M
Q3 23	$17M	-$83M	-$108M
Q4 23	$316M	$176M	$133M
Q1 24	$7M	-$77M	-$104M
Q2 24	$12M	$12M	-$105M
Q3 24	$14M	-$80M	-$107M
Q4 24	$30M	-$71M	-$100M
Q1 25	$7M	-$91M	-$119M
Q2 25	$8M	-$93M	-$120M
Q3 25	$10M	-$100M	-$127M
Q4 25	$114M	$108M	-$17M

Valuation

Quarter	P/S	P/E
Q1 22	67.3x	—
Q2 22	39.3x	—
Q3 22	36.9x	—
Q4 22	45.9x	—
Q1 23	30.0x	—
Q2 23	31.5x	—
Q3 23	21.3x	—
Q4 23	6.0x	—
Q1 24	7.4x	—
Q2 24	5.4x	—
Q3 24	5.8x	—
Q4 24	33.0x	—
Q1 25	31.3x	—
Q2 25	28.9x	—
Q3 25	44.0x	—
Q4 25	20.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$218M	$211M
Q2 22	-$52M	-$74M
Q3 22	-$74M	-$86M
Q4 22	-$69M	-$77M
Q1 23	-$110M	-$116M
Q2 23	-$85M	-$101M
Q3 23	-$90M	-$98M
Q4 23	$135M	$131M
Q1 24	-$100M	-$102M
Q2 24	-$83M	-$85M
Q3 24	-$88M	-$90M
Q4 24	-$76M	-$79M
Q1 25	-$104M	-$107M
Q2 25	-$76M	-$80M
Q3 25	-$81M	-$86M
Q4 25	-$83M	-$87M

Capital Expenditures

Quarter	CapEx
Q1 22	$7M
Q2 22	$22M
Q3 22	$12M
Q4 22	$8M
Q1 23	$6M
Q2 23	$16M
Q3 23	$8M
Q4 23	$4M
Q1 24	$2M
Q2 24	$2M
Q3 24	$2M
Q4 24	$3M
Q1 25	$3M
Q2 25	$3M
Q3 25	$5M
Q4 25	$4M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+140433.3%	-57.8%
Q2 22	+277433.3%	+67.2%
Q3 22	+1970.6%	+52.1%
Q4 22	-60.8%	-4.8%
Q1 23	+187.1%	+45.5%
Q2 23	+20.8%	+24.0%
Q3 23	+8.8%	+17.1%
Q4 23	+1478.0%	+68.2%
Q1 24	-69.4%	-9.4%
Q2 24	-41.5%	-4.6%
Q3 24	-17.0%	-3.7%
Q4 24	-90.5%	-29.0%
Q1 25	+0.8%	+13.6%
Q2 25	-28.1%	+10.2%
Q3 25	-32.0%	+13.0%
Q4 25	+279.5%	+1.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$18M	213.9%
Q2 22	$22M	129.6%
Q3 22	$22M	140.6%
Q4 22	$22M	112.3%
Q1 23	$24M	98.8%
Q2 23	$26M	130.6%
Q3 23	$26M	150.3%
Q4 23	$23M	7.2%
Q1 24	$29M	395.2%
Q2 24	$32M	268.5%
Q3 24	$30M	207.2%
Q4 24	$30M	100.5%
Q1 25	$27M	357.2%
Q2 25	$24M	287.8%
Q3 25	$23M	234.6%
Q4 25	-$74M	-64.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$65M	$19M
Q2 22	$75M	$24M
Q3 22	$85M	$22M
Q4 22	$86M	$23M
Q1 23	$100M	$23M
Q2 23	$98M	$25M
Q3 23	$100M	$25M
Q4 23	$140M	$43M
Q1 24	$85M	$27M
Q2 24	$87M	$30M
Q3 24	$94M	$27M
Q4 24	$101M	$29M
Q1 25	$99M	$28M
Q2 25	$102M	$27M
Q3 25	$110M	$27M
Q4 25	$99M	$27M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$297M	$926M	$1.2B
Q2 22	$266M	$900M	$1.2B
Q3 22	$157M	$938M	$1.1B
Q4 22	$233M	$845M	$1.1B
Q1 23	$250M	$810M	$1.1B
Q2 23	$226M	$847M	$1.1B
Q3 23	$169M	$846M	$1.0B
Q4 23	$436M	$754M	$1.2B
Q1 24	$288M	$807M	$1.1B
Q2 24	$293M	$715M	$1.0B
Q3 24	$230M	$696M	$926M
Q4 24	$282M	$569M	$851M
Q1 25	$528M	$692M	$1.2B
Q2 25	$282M	$868M	$1.2B
Q3 25	$268M	$807M	$1.1B
Q4 25	$295M	$950M	$1.2B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	69M	+1.1%	+14.1%
Q2 22	70M	+2.2%	+12.9%
Q3 22	70M	+0.2%	+6.0%
Q4 22	71M	+0.6%	+4.1%
Q1 23	72M	+2.1%	+5.2%
Q2 23	76M	+5.6%	+8.7%
Q3 23	79M	+3.5%	+12.3%
Q4 23	83M	+4.7%	+16.8%
Q1 24	82M	-1.2%	+13.0%
Q2 24	82M	+0.8%	+7.8%
Q3 24	82M	+0.1%	+4.3%
Q4 24	83M	+0.5%	+0.1%
Q1 25	88M	+6.2%	+7.7%
Q2 25	102M	+15.9%	+23.9%
Q3 25	103M	+0.6%	+24.5%
Q4 25	105M	+2.3%	+26.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$141	60K
Q2 22	$278	60K
Q3 22	$263	60K
Q4 22	$334	60K
Q1 23	$403	60K
Q2 23	$335	60K
Q3 23	$287	60K
Q4 23	$3.2K	100K
Q1 24	$74	100K
Q2 24	$118	100K
Q3 24	$143	100K
Q4 24	$301	100K
Q1 25	$75	100K
Q2 25	$85	100K
Q3 25	$97	100K
Q4 25	$1.1K	100K

Revenue / Employee